PEPTIDES
DECODED:
SCIENCE NOT
TIER LISTS
Peptides are biological signalling molecules — and one of the most misrepresented topics in fitness. Here's what the actual evidence says: which are clinically proven, which are experimental, which are overhyped, and what the real risks are.
I am a fitness content creator. This guide is purely educational — based on published research and publicly available scientific literature. Several peptides discussed here are prescription medications, research chemicals, or compounds with no human approval. Do not self-administer any peptide based on online content. Consult a licensed physician.
I am a fitness content creator. This is educational content based on published literature — not clinical advice from a physician or pharmacologist.
Most peptides discussed here are NOT approved for human use. Several are prescription drugs; others are unscheduled research chemicals with unknown safety profiles.
Tier lists and rankings you see online are scientifically meaningless. Evidence quality, dosing context, route of administration, and individual biology all matter enormously.
Underground market peptides carry serious purity risks. Mislabeling, contamination, and incorrect dosing from unregulated sources are well-documented and potentially dangerous.
Dosing information in this article is for educational reference only. Do not self-administer based on any online content including this one.
If you are considering peptide therapy for a medical reason, this must be assessed and supervised by a licensed endocrinologist or specialist physician.
What Peptides Actually
Are — The Real Biology
A peptide is a short chain of amino acids — typically 2 to 50 residues — linked by peptide bonds. Unlike proteins (which are longer chains folded into complex 3D structures), peptides are smaller, more specific, and typically function as biological signalling molecules rather than structural components.
The human body naturally produces thousands of endogenous peptides: insulin, glucagon, GLP-1, GH-releasing hormone (GHRH), and oxytocin are all peptides. What the fitness industry discusses are mostly synthetic analogues or derivatives of these naturally occurring molecules — engineered to mimic, amplify, or modulate the same pathways.
How Peptides Work — Four Core Mechanisms
receptors to trigger cascades
endogenous hormone release
break down target hormones
intracellular signalling pathways
The critical insight: specificity is everything. A peptide that activates GLP-1 receptors (semaglutide) does something completely different from one that stimulates GHRH receptors (sermorelin). Grouping them into "fat loss tier" or "recovery tier" lists ignores that they work through entirely distinct biological pathways with different safety profiles, evidence levels, and appropriate contexts.
Most peptides cannot be taken orally — they are broken down by digestive proteases before reaching systemic circulation. This is why most research-compound peptides are administered subcutaneously (injected under the skin) or intranasally. The injectable nature adds a layer of practical risk and complication that tier-list culture consistently ignores.
6 Categories: Ranked by
Evidence Strength, Not Hype
Instead of tier lists, here is a proper classification system based on evidence quality — from FDA-approved clinical agents down to early-stage experimental compounds. This is the framework that should replace "S-tier, A-tier" rankings.
This is the only peptide category with large-scale, multi-year, randomised controlled trial data in humans. These are approved pharmaceutical drugs — not supplements, not research chemicals. They represent the gold standard of what clinical evidence looks like for a peptide.
A synthetic analogue of GLP-1 (glucagon-like peptide-1) engineered for extended half-life (~7 days vs natural GLP-1's 2 min). Binds GLP-1 receptors in the hypothalamus, pancreas, and gut to simultaneously suppress appetite (via hypothalamic satiety centres), slow gastric emptying, and improve glucose-dependent insulin secretion. The SCALE and STEP trials demonstrated 15–17% body weight reduction over 68 weeks — the largest clinical weight loss results ever seen from a pharmacological intervention.
A dual agonist targeting both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors — the first in class. The SURMOUNT trials showed 22.5% average body weight reduction at maximum dose (15 mg/week), outperforming semaglutide in head-to-head comparisons. GIP agonism adds additional adipose tissue lipolysis signalling and potentially reduces the nausea ceiling that limits GLP-1 dose escalation. Currently the most potent pharmacological weight loss agent with clinical approval.
Semaglutide and tirzepatide are not performance supplements — they are prescription medications developed for type 2 diabetes and obesity management. Using them outside of medical supervision carries risks including pancreatitis, thyroid C-cell concerns, gallbladder disease, and severe GI complications. The "Ozempic for aesthetics" trend in fitness culture is using a powerful medical intervention without appropriate clinical oversight.
These peptides work via the growth hormone axis — either stimulating GHRH receptors to increase GH pulse amplitude, or mimicking ghrelin to trigger GH release via a separate receptor (GHSR). Real-world effects are more modest than the hype suggests because: (1) GH secretion is already tightly pulsatile and regulated, (2) additional GH pulses have diminishing marginal returns, and (3) GH does not directly cause muscle hypertrophy — IGF-1 downstream effects dominate, which are further context-dependent.
A 29-amino acid analogue of endogenous GHRH. Stimulates the pituitary to release GH in a physiological, pulsatile manner — rather than supraphysiological flooding as with exogenous GH. Clinical evidence supports modest improvements in GH secretion and body composition in growth hormone-deficient adults. Benefits in normal individuals are less clear. The most clinically studied GH secretagogue peptide, with an established safety profile relative to the GHRP class.
A modified GHRH analogue engineered for a dramatically extended half-life via DAC (Drug Affinity Complex) technology — binding to albumin to achieve 6–8 day half-life vs natural GHRH's ~7 minutes. This creates a sustained increase in GH pulse amplitude. Often combined with ipamorelin for synergistic action (GHRH + GHRP combination). Limited human trial data outside of one Phase 1 study. Effects on body composition require further controlled investigation in healthy adults.
A pentapeptide that acts as a selective ghrelin receptor (GHSR) agonist — triggering GH release via a different receptor than GHRH. Notably selective: does not significantly raise cortisol, prolactin, or ACTH, which distinguishes it from older GHRPs (GHRP-2, GHRP-6). Often used in combination with CJC-1295 for additive GH stimulation. Animal studies show anti-aging and muscle-sparing effects; human data is still limited.
Technically not a peptide — it's a small molecule ghrelin receptor agonist that is orally bioavailable (rare for this class). Demonstrated significant IGF-1 and GH elevation in several clinical trials. However, it also substantially increases appetite (via ghrelin pathway), causes water retention, and may worsen insulin sensitivity long-term. Often misclassified as a SARM. Falls into regulatory grey areas in most countries. Human data exists but is limited in scope and duration.
The healing peptides below have strong animal evidence — often remarkably dramatic in rodent studies — but almost no validated human clinical trial data. Animal-to-human translation in this class has historically been poor. The absence of human RCTs means dosing, safety, and efficacy in humans remain genuinely unknown. These are being used experimentally in the fitness community without a proper safety evidence base.
A 15-amino acid peptide derived from a protein found in gastric juice. Rodent studies show impressive healing effects: accelerated tendon, ligament, and muscle repair; reduced inflammation; enhanced angiogenesis (new blood vessel formation); neuroprotective effects; and gut mucosal healing. The proposed mechanism involves upregulating growth factor receptors (VEGFR, EGFR), activating FAK-paxillin pathways, and modulating nitric oxide synthesis. However, zero published randomised controlled trials in humans exist. All clinical assertions about BPC-157 in fitness are extrapolated from animal models.
A synthetic fragment of Thymosin Beta-4 (Tβ4) — a naturally occurring 43-amino acid peptide involved in actin polymerisation, cell migration, and wound healing. TB-500 specifically targets the actin-sequestering region of Tβ4. Animal studies show accelerated healing of wounds, tendons, ligaments, and cardiac tissue, along with anti-inflammatory effects. Human data is extremely limited: one small trial showed Tβ4 accelerated healing of pressure ulcers. No fitness-specific human trials exist. Used experimentally in equine medicine for musculoskeletal injuries.
A 70-amino acid peptide primarily produced in the liver in response to GH stimulation, and locally in muscle tissue (mechano growth factor). IGF-1 directly stimulates muscle protein synthesis via PI3K/Akt/mTOR pathway activation, promotes satellite cell proliferation, and has potent anti-apoptotic effects. Pharmaceutical IGF-1 (mecasermin) exists for IGF-1 deficiency treatment. In fitness context, supraphysiological IGF-1 carries serious risks: hypoglycaemia (IGF-1 acts insulin-like), acromegaly risk (organ and cartilage overgrowth), and markedly elevated cancer proliferation risk due to IGF-1's role in cellular growth promotion.
A 54-amino acid neuropeptide encoded by the KISS1 gene, acting on kisspeptin receptors (Kiss1R/GPR54) in the hypothalamus to trigger GnRH pulses — directly upstream of the LH/FSH/testosterone cascade. Used experimentally in endocrinology research as a tool to probe HPTA function in hypogonadism and infertility. Some interest in fitness community for HPTA stimulation post-cycle. No peer-reviewed evidence in the context of steroid PCT; all application is highly experimental and speculative.
A synthetic heptapeptide derived from ACTH (adrenocorticotropic hormone) fragments. Approved as a pharmaceutical in Russia for cognitive function, stroke recovery, and neuroprotection. Acts via BDNF (brain-derived neurotrophic factor) upregulation, enhancing neural plasticity and potentially protecting against neurodegeneration. Evidence base exists primarily in Russian-language literature; not replicated in large Western RCTs. Not approved or regulated in most Western countries.
A synthetic heptapeptide derived from the immunomodulatory peptide tuftsin, registered as a medication in Russia for anxiety and cognitive enhancement. Proposed mechanisms include modulating GABAergic transmission, BDNF expression, and IL-6/serotonin system activity. Russian clinical data suggests anxiolytic effects comparable to benzodiazepines without dependence risk. Limited to no replication in Western peer-reviewed literature. Fitness applications are speculative; primary interest is stress management and nootropic effects.
The peptides in this category have no validated human clinical evidence whatsoever. Evidence is restricted to cell cultures or animal models. Human pharmacokinetics, toxicology, long-term effects, and dosing are unknown. These are research tools for laboratory use — not compounds for human self-administration under any circumstances.
A D-amino acid retro-inverso peptide that disrupts the FOXO4-p53 protein interaction in senescent cells, triggering selective apoptosis of senescent cells without affecting healthy cells — in mouse models. One landmark 2017 Nature Medicine mouse study showed remarkable rejuvenation effects in aged mice. Zero human clinical trials exist. The jump from mouse senescence studies to human anti-aging use is scientifically unjustifiable at this stage.
A small peptide derived from angiotensin IV, proposed to enhance cognitive function via HGF/c-Met signalling — promoting synaptogenesis (new synaptic connections). One study suggested it was orders of magnitude more potent than BDNF in promoting synaptic density in rodents. Absolutely no human clinical data exists. The compound has never been through Phase 1 human trials. Human toxicology, blood-brain barrier penetration in humans, and long-term neurological effects are completely unknown.
Reference Dosing: Research
Literature Figures Only
All dosing below is derived from clinical trial literature and research publications — not personal recommendations. Never self-dose based on online content.
These figures are from published research papers, clinical trial protocols, and established medical literature. They are presented so you can understand the research context — not to guide self-administration. Individual response, purity of source, administration route, and health status all critically affect dosing safety. I am not a doctor. Do not self-administer.
Clinically Approved Metabolic Peptides — Prescription Required
| Peptide | Clinical Starting Dose | Titration | Max Clinical Dose | Route |
|---|---|---|---|---|
| Semaglutide (obesity) | 0.25 mg/week | Increase every 4 weeks | 2.4 mg/week | Subcutaneous |
| Tirzepatide (obesity) | 2.5 mg/week | +2.5 mg every 4 weeks | 15 mg/week | Subcutaneous |
GH-Axis Peptides — Limited Human Trial Data
| Peptide | Research Dose Range | Frequency | Duration (Studied) | Route |
|---|---|---|---|---|
| Sermorelin | 200–500 mcg | Once daily (pre-sleep) | 3–6 months (GHD protocols) | Subcutaneous |
| CJC-1295 (with DAC) | 1–2 mg | Once weekly | Short-term studies only | Subcutaneous |
| Ipamorelin | 100–300 mcg | 1–3x daily (pulsatile) | Short-term studies only | Subcutaneous |
| MK-677 (Ibutamoren) | 10–25 mg | Once daily (oral) | Up to 12 months in trials | Oral |
| CJC-1295 + Ipamorelin (combo) | 100 mcg each | 2–3x daily | No long-term study | Subcutaneous |
Tissue Repair Peptides — Animal-Derived Reference Doses Only
| Peptide | Extrapolated Dose* | Frequency | Cycle Duration | Route |
|---|---|---|---|---|
| BPC-157 | 200–500 mcg/day | Once or twice daily | 4–8 weeks (no human data) | Subcut. or oral (stability unclear) |
| TB-500 | 2–2.5 mg/week (loading) | Weekly (then biweekly) | 4–6 week loading, then taper | Subcutaneous |
*Extrapolated from animal studies using body surface area scaling — not validated human clinical doses. Unknown safety in humans.
Route of administration, purity, peptide stability, and individual receptor sensitivity all affect dose-response. BPC-157 administered subcutaneously vs orally may have completely different bioavailability profiles. GHRP combinations require precise timing relative to natural GH pulsatility to avoid blunting response. These nuances are absent from all fitness tier list content.
Real Risks Most Tier
Lists Never Mention
Hormonal Disruption
GH-axis and IGF-1 pathway manipulation can affect insulin sensitivity, glucose metabolism, organ sizing, and thyroid function. Supraphysiological GH/IGF-1 exposure is associated with insulin resistance and potential carcinogenic risk due to IGF-1's mitogenic (cell growth promoting) activity.
Unknown Long-Term Safety
For most peptides discussed in fitness contexts — especially BPC-157, TB-500, and the experimental category — there are literally no long-term human safety studies. "No evidence of harm" is not the same as "evidence of safety." Unknown is dangerous.
Underground Source Contamination
The vast majority of research peptides available to consumers come from unregulated manufacturers with no quality control obligation. Studies testing purity of market peptides frequently find mislabeling (wrong compound), wrong concentration, and bacterial endotoxin contamination — which causes severe immune reactions on injection.
Injection Infection Risk
Subcutaneous injection with non-sterile technique, non-bacteriostatic water reconstitution, or contaminated vials carries real risk of abscess, cellulitis, and systemic infection. Most fitness users are not trained in aseptic injection technique.
Legal & Regulatory Status
Peptide legal status varies dramatically by jurisdiction. Semaglutide and tirzepatide are prescription-only in all countries. GHRH/GHRP peptides are unscheduled in some regions, controlled in others. Several are banned by WADA for competitive athletes. Selling "research peptides for human use" exists in a regulatory grey zone that can shift.
Drug Interaction Risks
GLP-1 agonists significantly affect gastric motility and can alter absorption of other medications. GH secretagogues affect insulin sensitivity and interact with diabetes medications. Neurological peptides modulate GABAergic and serotonergic systems that interact with psychiatric medications. These interactions are not hypothetical.
Tier List Overclaiming
The immediate practical risk: spending significant money on compounds that have no validated human evidence of the specific claimed effect (injury healing, muscle gain, fat loss at physiological doses). The opportunity cost of chasing experimental compounds vs. optimising fundamentals is itself a significant fitness risk.
Diagnostic Interference
Several peptides affect biomarkers that doctors use to diagnose disease. GH secretagogues elevate IGF-1; GLP-1 agonists affect glucose regulation; BPC-157 may modulate inflammatory markers. Self-administering these compounds can complicate accurate medical diagnosis if health issues arise.
What Actually Works for
Fitness Goals — Without Peptides
Here's the framework that is consistently more powerful than any peptide protocol for fitness outcomes — built on decades of human RCT data, not animal studies or anecdotal reports.
The appeal of peptides is often inversely proportional to how well someone's fundamentals are optimised. The greatest gains available to 99% of people are still untouched in their training programme, protein intake, and sleep quality.
Fat Loss — Calorie Deficit Outperforms All Compounds
Even semaglutide — the most potent pharmacological fat loss agent with the best human evidence — produces 15–22% body weight reduction. A well-executed calorie deficit with high protein and resistance training produces comparable body composition improvements without pharmaceutical risk, cost, or regulatory concern for most people starting from baseline.
Muscle Growth — Mechanical Tension and Protein Remain Primary
The PI3K/Akt/mTOR pathway that IGF-1 and GH agonists are trying to influence is directly and powerfully activated by mechanical load during resistance training — with no pharmaceutical intervention required. Progressive overload combined with adequate leucine intake (3+ grams per meal) maximally stimulates muscle protein synthesis through the same downstream pathways.
Recovery — Sleep Is a More Powerful GH Stimulus Than Any Peptide
The largest natural GH pulse of the day occurs during the first slow-wave sleep cycle — typically producing a pulse far greater in amplitude than that achieved by GHRH peptides at standard doses. Optimising sleep quality directly optimises the GH/IGF-1 axis, tissue repair, and inflammation resolution — free, legal, and with an exceptional evidence base.
GLP-1 agonists for clinically diagnosed obesity or type 2 diabetes — under physician supervision. GH secretagogues for documented growth hormone deficiency — under endocrinologist supervision. Possibly peptide therapeutics for specific injury conditions in clinical settings as evidence develops. These are narrow, medically supervised use cases — not general fitness optimisation tools.
Peptide Myths That
Cost Money and Health
+Consistency Over Time+Peptides (narrow clinical use only)
I am a fitness content creator, not a doctor or pharmacologist — and this article is not a guide to using peptides. It's a guide to understanding why most of what you read about peptides is oversimplified, under-evidenced, or outright misleading. Some peptides are genuinely remarkable medical tools. Most fitness applications are speculative. All of them carry risks that tier lists never mention. Understand the science. Respect the evidence levels. And if you're considering medical-grade compounds for a clinical condition — please see an actual doctor.
PEPTIDES
DECODED:
SCIENCE NOT
TIER LISTS
Peptides are biological signalling molecules — and one of the most misrepresented topics in fitness. Here's what the actual evidence says: which are clinically proven, which are experimental, which are overhyped, and what the real risks are.
I am a fitness content creator. This guide is purely educational — based on published research and publicly available scientific literature. Several peptides discussed here are prescription medications, research chemicals, or compounds with no human approval. Do not self-administer any peptide based on online content. Consult a licensed physician.
I am a fitness content creator. This is educational content based on published literature — not clinical advice from a physician or pharmacologist.
Most peptides discussed here are NOT approved for human use. Several are prescription drugs; others are unscheduled research chemicals with unknown safety profiles.
Tier lists and rankings you see online are scientifically meaningless. Evidence quality, dosing context, route of administration, and individual biology all matter enormously.
Underground market peptides carry serious purity risks. Mislabeling, contamination, and incorrect dosing from unregulated sources are well-documented and potentially dangerous.
Dosing information in this article is for educational reference only. Do not self-administer based on any online content including this one.
If you are considering peptide therapy for a medical reason, this must be assessed and supervised by a licensed endocrinologist or specialist physician.
What Peptides Actually
Are — The Real Biology
A peptide is a short chain of amino acids — typically 2 to 50 residues — linked by peptide bonds. Unlike proteins (which are longer chains folded into complex 3D structures), peptides are smaller, more specific, and typically function as biological signalling molecules rather than structural components.
The human body naturally produces thousands of endogenous peptides: insulin, glucagon, GLP-1, GH-releasing hormone (GHRH), and oxytocin are all peptides. What the fitness industry discusses are mostly synthetic analogues or derivatives of these naturally occurring molecules — engineered to mimic, amplify, or modulate the same pathways.
How Peptides Work — Four Core Mechanisms
receptors to trigger cascades
endogenous hormone release
break down target hormones
intracellular signalling pathways
The critical insight: specificity is everything. A peptide that activates GLP-1 receptors (semaglutide) does something completely different from one that stimulates GHRH receptors (sermorelin). Grouping them into "fat loss tier" or "recovery tier" lists ignores that they work through entirely distinct biological pathways with different safety profiles, evidence levels, and appropriate contexts.
Most peptides cannot be taken orally — they are broken down by digestive proteases before reaching systemic circulation. This is why most research-compound peptides are administered subcutaneously (injected under the skin) or intranasally. The injectable nature adds a layer of practical risk and complication that tier-list culture consistently ignores.
6 Categories: Ranked by
Evidence Strength, Not Hype
Instead of tier lists, here is a proper classification system based on evidence quality — from FDA-approved clinical agents down to early-stage experimental compounds. This is the framework that should replace "S-tier, A-tier" rankings.
This is the only peptide category with large-scale, multi-year, randomised controlled trial data in humans. These are approved pharmaceutical drugs — not supplements, not research chemicals. They represent the gold standard of what clinical evidence looks like for a peptide.
A synthetic analogue of GLP-1 (glucagon-like peptide-1) engineered for extended half-life (~7 days vs natural GLP-1's 2 min). Binds GLP-1 receptors in the hypothalamus, pancreas, and gut to simultaneously suppress appetite (via hypothalamic satiety centres), slow gastric emptying, and improve glucose-dependent insulin secretion. The SCALE and STEP trials demonstrated 15–17% body weight reduction over 68 weeks — the largest clinical weight loss results ever seen from a pharmacological intervention.
A dual agonist targeting both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors — the first in class. The SURMOUNT trials showed 22.5% average body weight reduction at maximum dose (15 mg/week), outperforming semaglutide in head-to-head comparisons. GIP agonism adds additional adipose tissue lipolysis signalling and potentially reduces the nausea ceiling that limits GLP-1 dose escalation. Currently the most potent pharmacological weight loss agent with clinical approval.
Semaglutide and tirzepatide are not performance supplements — they are prescription medications developed for type 2 diabetes and obesity management. Using them outside of medical supervision carries risks including pancreatitis, thyroid C-cell concerns, gallbladder disease, and severe GI complications. The "Ozempic for aesthetics" trend in fitness culture is using a powerful medical intervention without appropriate clinical oversight.
These peptides work via the growth hormone axis — either stimulating GHRH receptors to increase GH pulse amplitude, or mimicking ghrelin to trigger GH release via a separate receptor (GHSR). Real-world effects are more modest than the hype suggests because: (1) GH secretion is already tightly pulsatile and regulated, (2) additional GH pulses have diminishing marginal returns, and (3) GH does not directly cause muscle hypertrophy — IGF-1 downstream effects dominate, which are further context-dependent.
A 29-amino acid analogue of endogenous GHRH. Stimulates the pituitary to release GH in a physiological, pulsatile manner — rather than supraphysiological flooding as with exogenous GH. Clinical evidence supports modest improvements in GH secretion and body composition in growth hormone-deficient adults. Benefits in normal individuals are less clear. The most clinically studied GH secretagogue peptide, with an established safety profile relative to the GHRP class.
A modified GHRH analogue engineered for a dramatically extended half-life via DAC (Drug Affinity Complex) technology — binding to albumin to achieve 6–8 day half-life vs natural GHRH's ~7 minutes. This creates a sustained increase in GH pulse amplitude. Often combined with ipamorelin for synergistic action (GHRH + GHRP combination). Limited human trial data outside of one Phase 1 study. Effects on body composition require further controlled investigation in healthy adults.
A pentapeptide that acts as a selective ghrelin receptor (GHSR) agonist — triggering GH release via a different receptor than GHRH. Notably selective: does not significantly raise cortisol, prolactin, or ACTH, which distinguishes it from older GHRPs (GHRP-2, GHRP-6). Often used in combination with CJC-1295 for additive GH stimulation. Animal studies show anti-aging and muscle-sparing effects; human data is still limited.
Technically not a peptide — it's a small molecule ghrelin receptor agonist that is orally bioavailable (rare for this class). Demonstrated significant IGF-1 and GH elevation in several clinical trials. However, it also substantially increases appetite (via ghrelin pathway), causes water retention, and may worsen insulin sensitivity long-term. Often misclassified as a SARM. Falls into regulatory grey areas in most countries. Human data exists but is limited in scope and duration.
The healing peptides below have strong animal evidence — often remarkably dramatic in rodent studies — but almost no validated human clinical trial data. Animal-to-human translation in this class has historically been poor. The absence of human RCTs means dosing, safety, and efficacy in humans remain genuinely unknown. These are being used experimentally in the fitness community without a proper safety evidence base.
A 15-amino acid peptide derived from a protein found in gastric juice. Rodent studies show impressive healing effects: accelerated tendon, ligament, and muscle repair; reduced inflammation; enhanced angiogenesis (new blood vessel formation); neuroprotective effects; and gut mucosal healing. The proposed mechanism involves upregulating growth factor receptors (VEGFR, EGFR), activating FAK-paxillin pathways, and modulating nitric oxide synthesis. However, zero published randomised controlled trials in humans exist. All clinical assertions about BPC-157 in fitness are extrapolated from animal models.
A synthetic fragment of Thymosin Beta-4 (Tβ4) — a naturally occurring 43-amino acid peptide involved in actin polymerisation, cell migration, and wound healing. TB-500 specifically targets the actin-sequestering region of Tβ4. Animal studies show accelerated healing of wounds, tendons, ligaments, and cardiac tissue, along with anti-inflammatory effects. Human data is extremely limited: one small trial showed Tβ4 accelerated healing of pressure ulcers. No fitness-specific human trials exist. Used experimentally in equine medicine for musculoskeletal injuries.
A 70-amino acid peptide primarily produced in the liver in response to GH stimulation, and locally in muscle tissue (mechano growth factor). IGF-1 directly stimulates muscle protein synthesis via PI3K/Akt/mTOR pathway activation, promotes satellite cell proliferation, and has potent anti-apoptotic effects. Pharmaceutical IGF-1 (mecasermin) exists for IGF-1 deficiency treatment. In fitness context, supraphysiological IGF-1 carries serious risks: hypoglycaemia (IGF-1 acts insulin-like), acromegaly risk (organ and cartilage overgrowth), and markedly elevated cancer proliferation risk due to IGF-1's role in cellular growth promotion.
A 54-amino acid neuropeptide encoded by the KISS1 gene, acting on kisspeptin receptors (Kiss1R/GPR54) in the hypothalamus to trigger GnRH pulses — directly upstream of the LH/FSH/testosterone cascade. Used experimentally in endocrinology research as a tool to probe HPTA function in hypogonadism and infertility. Some interest in fitness community for HPTA stimulation post-cycle. No peer-reviewed evidence in the context of steroid PCT; all application is highly experimental and speculative.
A synthetic heptapeptide derived from ACTH (adrenocorticotropic hormone) fragments. Approved as a pharmaceutical in Russia for cognitive function, stroke recovery, and neuroprotection. Acts via BDNF (brain-derived neurotrophic factor) upregulation, enhancing neural plasticity and potentially protecting against neurodegeneration. Evidence base exists primarily in Russian-language literature; not replicated in large Western RCTs. Not approved or regulated in most Western countries.
A synthetic heptapeptide derived from the immunomodulatory peptide tuftsin, registered as a medication in Russia for anxiety and cognitive enhancement. Proposed mechanisms include modulating GABAergic transmission, BDNF expression, and IL-6/serotonin system activity. Russian clinical data suggests anxiolytic effects comparable to benzodiazepines without dependence risk. Limited to no replication in Western peer-reviewed literature. Fitness applications are speculative; primary interest is stress management and nootropic effects.
The peptides in this category have no validated human clinical evidence whatsoever. Evidence is restricted to cell cultures or animal models. Human pharmacokinetics, toxicology, long-term effects, and dosing are unknown. These are research tools for laboratory use — not compounds for human self-administration under any circumstances.
A D-amino acid retro-inverso peptide that disrupts the FOXO4-p53 protein interaction in senescent cells, triggering selective apoptosis of senescent cells without affecting healthy cells — in mouse models. One landmark 2017 Nature Medicine mouse study showed remarkable rejuvenation effects in aged mice. Zero human clinical trials exist. The jump from mouse senescence studies to human anti-aging use is scientifically unjustifiable at this stage.
A small peptide derived from angiotensin IV, proposed to enhance cognitive function via HGF/c-Met signalling — promoting synaptogenesis (new synaptic connections). One study suggested it was orders of magnitude more potent than BDNF in promoting synaptic density in rodents. Absolutely no human clinical data exists. The compound has never been through Phase 1 human trials. Human toxicology, blood-brain barrier penetration in humans, and long-term neurological effects are completely unknown.
Reference Dosing: Research
Literature Figures Only
All dosing below is derived from clinical trial literature and research publications — not personal recommendations. Never self-dose based on online content.
These figures are from published research papers, clinical trial protocols, and established medical literature. They are presented so you can understand the research context — not to guide self-administration. Individual response, purity of source, administration route, and health status all critically affect dosing safety. I am not a doctor. Do not self-administer.
Clinically Approved Metabolic Peptides — Prescription Required
| Peptide | Clinical Starting Dose | Titration | Max Clinical Dose | Route |
|---|---|---|---|---|
| Semaglutide (obesity) | 0.25 mg/week | Increase every 4 weeks | 2.4 mg/week | Subcutaneous |
| Tirzepatide (obesity) | 2.5 mg/week | +2.5 mg every 4 weeks | 15 mg/week | Subcutaneous |
GH-Axis Peptides — Limited Human Trial Data
| Peptide | Research Dose Range | Frequency | Duration (Studied) | Route |
|---|---|---|---|---|
| Sermorelin | 200–500 mcg | Once daily (pre-sleep) | 3–6 months (GHD protocols) | Subcutaneous |
| CJC-1295 (with DAC) | 1–2 mg | Once weekly | Short-term studies only | Subcutaneous |
| Ipamorelin | 100–300 mcg | 1–3x daily (pulsatile) | Short-term studies only | Subcutaneous |
| MK-677 (Ibutamoren) | 10–25 mg | Once daily (oral) | Up to 12 months in trials | Oral |
| CJC-1295 + Ipamorelin (combo) | 100 mcg each | 2–3x daily | No long-term study | Subcutaneous |
Tissue Repair Peptides — Animal-Derived Reference Doses Only
| Peptide | Extrapolated Dose* | Frequency | Cycle Duration | Route |
|---|---|---|---|---|
| BPC-157 | 200–500 mcg/day | Once or twice daily | 4–8 weeks (no human data) | Subcut. or oral (stability unclear) |
| TB-500 | 2–2.5 mg/week (loading) | Weekly (then biweekly) | 4–6 week loading, then taper | Subcutaneous |
*Extrapolated from animal studies using body surface area scaling — not validated human clinical doses. Unknown safety in humans.
Route of administration, purity, peptide stability, and individual receptor sensitivity all affect dose-response. BPC-157 administered subcutaneously vs orally may have completely different bioavailability profiles. GHRP combinations require precise timing relative to natural GH pulsatility to avoid blunting response. These nuances are absent from all fitness tier list content.
Real Risks Most Tier
Lists Never Mention
Hormonal Disruption
GH-axis and IGF-1 pathway manipulation can affect insulin sensitivity, glucose metabolism, organ sizing, and thyroid function. Supraphysiological GH/IGF-1 exposure is associated with insulin resistance and potential carcinogenic risk due to IGF-1's mitogenic (cell growth promoting) activity.
Unknown Long-Term Safety
For most peptides discussed in fitness contexts — especially BPC-157, TB-500, and the experimental category — there are literally no long-term human safety studies. "No evidence of harm" is not the same as "evidence of safety." Unknown is dangerous.
Underground Source Contamination
The vast majority of research peptides available to consumers come from unregulated manufacturers with no quality control obligation. Studies testing purity of market peptides frequently find mislabeling (wrong compound), wrong concentration, and bacterial endotoxin contamination — which causes severe immune reactions on injection.
Injection Infection Risk
Subcutaneous injection with non-sterile technique, non-bacteriostatic water reconstitution, or contaminated vials carries real risk of abscess, cellulitis, and systemic infection. Most fitness users are not trained in aseptic injection technique.
Legal & Regulatory Status
Peptide legal status varies dramatically by jurisdiction. Semaglutide and tirzepatide are prescription-only in all countries. GHRH/GHRP peptides are unscheduled in some regions, controlled in others. Several are banned by WADA for competitive athletes. Selling "research peptides for human use" exists in a regulatory grey zone that can shift.
Drug Interaction Risks
GLP-1 agonists significantly affect gastric motility and can alter absorption of other medications. GH secretagogues affect insulin sensitivity and interact with diabetes medications. Neurological peptides modulate GABAergic and serotonergic systems that interact with psychiatric medications. These interactions are not hypothetical.
Tier List Overclaiming
The immediate practical risk: spending significant money on compounds that have no validated human evidence of the specific claimed effect (injury healing, muscle gain, fat loss at physiological doses). The opportunity cost of chasing experimental compounds vs. optimising fundamentals is itself a significant fitness risk.
Diagnostic Interference
Several peptides affect biomarkers that doctors use to diagnose disease. GH secretagogues elevate IGF-1; GLP-1 agonists affect glucose regulation; BPC-157 may modulate inflammatory markers. Self-administering these compounds can complicate accurate medical diagnosis if health issues arise.
What Actually Works for
Fitness Goals — Without Peptides
Here's the framework that is consistently more powerful than any peptide protocol for fitness outcomes — built on decades of human RCT data, not animal studies or anecdotal reports.
The appeal of peptides is often inversely proportional to how well someone's fundamentals are optimised. The greatest gains available to 99% of people are still untouched in their training programme, protein intake, and sleep quality.
Fat Loss — Calorie Deficit Outperforms All Compounds
Even semaglutide — the most potent pharmacological fat loss agent with the best human evidence — produces 15–22% body weight reduction. A well-executed calorie deficit with high protein and resistance training produces comparable body composition improvements without pharmaceutical risk, cost, or regulatory concern for most people starting from baseline.
Muscle Growth — Mechanical Tension and Protein Remain Primary
The PI3K/Akt/mTOR pathway that IGF-1 and GH agonists are trying to influence is directly and powerfully activated by mechanical load during resistance training — with no pharmaceutical intervention required. Progressive overload combined with adequate leucine intake (3+ grams per meal) maximally stimulates muscle protein synthesis through the same downstream pathways.
Recovery — Sleep Is a More Powerful GH Stimulus Than Any Peptide
The largest natural GH pulse of the day occurs during the first slow-wave sleep cycle — typically producing a pulse far greater in amplitude than that achieved by GHRH peptides at standard doses. Optimising sleep quality directly optimises the GH/IGF-1 axis, tissue repair, and inflammation resolution — free, legal, and with an exceptional evidence base.
GLP-1 agonists for clinically diagnosed obesity or type 2 diabetes — under physician supervision. GH secretagogues for documented growth hormone deficiency — under endocrinologist supervision. Possibly peptide therapeutics for specific injury conditions in clinical settings as evidence develops. These are narrow, medically supervised use cases — not general fitness optimisation tools.
Peptide Myths That
Cost Money and Health
+Consistency Over Time+Peptides (narrow clinical use only)
I am a fitness content creator, not a doctor or pharmacologist — and this article is not a guide to using peptides. It's a guide to understanding why most of what you read about peptides is oversimplified, under-evidenced, or outright misleading. Some peptides are genuinely remarkable medical tools. Most fitness applications are speculative. All of them carry risks that tier lists never mention. Understand the science. Respect the evidence levels. And if you're considering medical-grade compounds for a clinical condition — please see an actual doctor.